Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$207.13
-0.4%		$202.63
$127.71
▼
$219.72
$30.72B0.171.35 million shs706,405 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$68.88
+7.9%		$58.47
$49.26
▼
$69.27
$12.35B0.241.85 million shs5.04 million shs
Natera, Inc. stock logo
NTRA
Natera
$318.35
-1.2%		$256.02
$149.38
▼
$326.03
$46.13B1.511.19 million shs2.15 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$206.97
+0.9%		$177.53
$34.14
▼
$208.76
$43.97B1.391.87 million shs2.10 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.39%+2.63%+4.01%+3.90%+58.51%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+7.95%+14.82%+16.51%+30.26%+20.15%
Natera, Inc. stock logo
NTRA
Natera
-1.16%+17.75%+17.93%+55.89%+109.51%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.89%+13.44%+10.75%+42.03%+491.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$207.13
-0.4%		$202.63
$127.71
▼
$219.72
$30.72B0.171.35 million shs706,405 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$68.88
+7.9%		$58.47
$49.26
▼
$69.27
$12.35B0.241.85 million shs5.04 million shs
Natera, Inc. stock logo
NTRA
Natera
$318.35
-1.2%		$256.02
$149.38
▼
$326.03
$46.13B1.511.19 million shs2.15 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$206.97
+0.9%		$177.53
$34.14
▼
$208.76
$43.97B1.391.87 million shs2.10 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.39%+2.63%+4.01%+3.90%+58.51%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+7.95%+14.82%+16.51%+30.26%+20.15%
Natera, Inc. stock logo
NTRA
Natera
-1.16%+17.75%+17.93%+55.89%+109.51%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.89%+13.44%+10.75%+42.03%+491.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.56
Moderate Buy$224.618.44% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.71
Moderate Buy$88.0027.76% Upside
Natera, Inc. stock logo
NTRA
Natera
2.77
Moderate Buy$301.90-5.17% Downside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.91
Moderate Buy$160.68-22.36% Downside

Current Analyst Ratings Breakdown

Latest BMRN, NTRA, RVMD, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
Natera, Inc. stock logo
NTRA
Natera
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$355.00
8/10/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$220.00
8/10/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$111.00 ➝ $114.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $340.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$275.00 ➝ $350.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$348.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$375.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$220.00 ➝ $284.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$300.00 ➝ $315.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $320.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$330.00
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$10.03B3.05$22.54 per share9.19$124.45 per share1.66
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B4.14$3.08 per share22.36$31.68 per share2.17
Natera, Inc. stock logo
NTRA
Natera
$2.31B19.77N/AN/A$12.38 per share25.71
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,830.91N/AN/A$8.44 per share24.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6536.6612.646.428.32%11.18%6.88%10/29/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37186.1612.230.492.14%5.32%3.69%10/26/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/AN/AN/A-7.11%-11.82%-8.19%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%N/A

Latest BMRN, NTRA, RVMD, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Natera, Inc. stock logo
NTRA
Natera
N/A
2.96
2.83
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140143.21 million135.98 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-sets-new-12-month-high-should-you-buy-2026-08-11/
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-cuts-holdings-in-revolution-medicines-inc-rvmd-2026-08-11/
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10 at 6:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260810801799/en/beone-medicines-and-revolution-medicines-announce-clinical-development-and-regional-commercialization-collaboration/
Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)
August 9 at 3:02 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3745020/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd/
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD
August 9 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-buys-shares-of-200486-revolution-medicines-inc-rvmd-2026-08-09/
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $240.00
August 9 at 2:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949765
Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD
August 8 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-cuts-holdings-in-revolution-medicines-inc-rvmd-2026-08-08/
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug
August 7, 2026  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2026/08/07/pancreatic-cancer-daraxonrasib-revolution-rvmd.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/URGN/pressreleases/3717834/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revolution-medicines-rvmd-royalty-pharma-rprx-and-urogen-pharma-urgn/
High Risk, High Reward: Inside The Revolution Medicines Bull Case
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932810-high-risk-high-reward-inside-the-revolution-medicines-bull-case
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970347/rvmd-posts-wider-than-anticipated-loss-in-q2-lifts-26-expense-view?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970347
Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/needham-company-llc-raises-revolution-medicines-nasdaqrvmd-price-target-to-24000-2026-08-06/
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-boosts-stake-in-revolution-medicines-inc-rvmd-2026-08-06/
Revolution Medicines Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-q2-earnings-call-highlights-2026-08-05/
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-announces-earnings-results-2026-08-05/
Revolution Medicines Q2 Net Loss Widens
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-q2-net-loss-212551304.html
Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4627060-revolution-medicines-updates-2026-gaap-operating-expenses-to-2_1b-2_2b-while-preparing
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339656/0/en/revolution-medicines-reports-second-quarter-2026-financial-results-and-update-on-corporate-progress.html
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - Time to Buy?
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-sets-new-1-year-high-time-to-buy-2026-08-05/
Amundi Buys 118,493 Shares of Revolution Medicines, Inc. $RVMD
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-buys-118493-shares-of-revolution-medicines-inc-rvmd-2026-08-05/
Royal Bank of Canada Sells 131,978 Shares of Revolution Medicines, Inc. $RVMD
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-sells-131978-shares-of-revolution-medicines-inc-rvmd-2026-08-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Steam rises from a power plant cooling tower silhouetted against a glowing sunset sky.
3 Energy Stocks Racing to Fix AI's Power Problem
By Bridget Bennett | July 14, 2026
Aerial view of a water treatment plant with circular clarifiers, pipelines, and a reservoir behind it.
These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending
By Nathan Reiff | July 14, 2026
Palantir-branded sphere glows in a server room with AI graphics, underscoring the company’s enterprise AI capabilities.
Palantir's Wild Ride: Inside the Stock Wall Street Can't Agree On
By Chris Markoch | July 17, 2026
Rocket Lab Electron rocket lifts off from coastal pad, plume and smoke rising beside Rocket Lab logo.
Rocket Lab Has Corrected Nearly 50%—Is It Still Too Expensive?
By Ryan Hasson | July 23, 2026
Biogen stock logo

Biogen NASDAQ:BIIB

$207.13 -0.81 (-0.39%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$208.46 +1.33 (+0.64%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$68.88 +5.07 (+7.95%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$68.93 +0.05 (+0.07%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Natera stock logo

Natera NASDAQ:NTRA

$318.35 -3.75 (-1.16%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$315.90 -2.45 (-0.77%)
As of 05:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$206.97 +1.82 (+0.89%)
Closing price 08/10/2026 04:00 PM Eastern
Extended Trading
$205.35 -1.62 (-0.78%)
As of 05:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas